BIO-key International delivered a quarter that looks far worse on the headline than in the underlying software business, though it was still not a good quarter. The company reported a loss of $4.01 per share on revenue of $1.48 million. That missed the -$0.35 consensus by 1045.7%, and revenue fell 38.2% short of the $2.4 million estimate. Earnings fell 2573.3% year over year and revenue declined 4.3%. Much of the per-share damage came from a $4.5 million non-cash deemed dividend tied to the August warrant inducement. Excluding it, the net loss actually narrowed to $886,000 from $965,000 a year ago. But that adjustment does not rescue the quarter. Even the $886,000 net loss, spread over 1.34 million weighted shares, works out to roughly $0.66 per share, which is still well short of consensus. The revenue miss is the real problem. That is the central tension: a software franchise that keeps getting better is attached to a top line that has slid from growth into decline.

The mix shift underneath is real. License fee revenue rose 39% to $1.28 million and now makes up 86% of sales, up from 59% a year ago. That lifted gross margin to 90% from 77%. It was the fifth straight quarterly improvement, and the cost-of-hardware reserve benefit was negligible this time, so the margin gain was not flattered by an accounting item. The EMESA region (Europe, the Middle East and South America) grew 39%, with license fees more than doubling to $903,000. The weakness came from the episodic lines. Hardware revenue collapsed to $12,000 from $364,000, and services fell 27%. Operating expenses rose 4% year over year, although they eased 2% sequentially.

The call made the deceleration hard to ignore. Total revenue growth has gone from +34% in Q1 to +13% in Q2 to -4% in Q3. Hardware has fallen from $531,000 to $460,000 to $12,000 over the same stretch. A large international hardware order that has been delayed since Q2 is still arriving only in small tranches. The net loss has widened sequentially in each quarter, from $165,000 to $577,000 to $886,000. So the release's year-over-year framing of a narrowing loss is accurate but incomplete. Management's profitability target has also slipped for the second consecutive call. It moved from Q2 2026, to the second half of 2026, and now to roughly early 2027. First-half revenue of about $4.0 million also fell short of the roughly $5 million implied on the Q1 call. Bears have legitimate ammunition on credibility.

The catalyst list, however, is longer and more concrete than in prior quarters:

• **New customers:** BIO-key has added eight Middle East customers in about seven months, and the Central Bank of Jordan initiative is moving toward deployment.
• **New market:** A multiple-six-figure, prepaid three-year PortalGuard deal with a U.S. casino resort opens gaming and hospitality. It will be recognized in Q4.
• **Channel and leadership:** BIO-key announced the Cipher/Prosegur integration starting in Portugal, a Gulf partnership, a Saudi subsidiary and a new PortalGuard president aimed at the U.S. market, where business was described as basically flat.
• **AI opportunity:** The FIDO-certified Passkey:YOU authenticator underpins an agentic-AI authorization product slated for Q4 deployment.
• **Near-term outlook:** Management guided Q4 to significant growth over last year's $1.188 million and expects about $1.2 million of Q1 2027 renewals, including more than $1 million from its largest customer.

The balance sheet improved. The note is retired, working capital rose to $3.1 million from $0.8 million in June, and management says no capital raise is needed. Even so, cash slipped to $2.2 million from $2.7 million at year-end, and receivables doubled to $2.4 million. That raises collection-timing questions through partner channels.

Other risks remain. Nasdaq is monitoring the company through July 2027 after a trading suspension earlier this year. About 1.2 million warrants at $4.06 add a dilution overhang if the shares recover.

Investor sentiment remains negative but has improved meaningfully, rising from -0.83 to -0.54 heading into the report. That suggests expectations were already low. Price action has been volatile. Shares spiked to $4.66 in late September, collapsed to $1.55 by mid-October and closed at $2.58 the day before the report. That leaves them 17.8% below the post-Q2 opening price and just under the $2.65 200-day moving average. Price and AVWAP trend readings remain negative, while sequential-growth and momentum readings are neutral.

The bottom line is that BIO-key's software engine, margin profile and regulated-sector customer wins are improving, but the company again failed to deliver the revenue and profitability it previously signaled. The Q4 guide for significant growth and the Q1 renewal cycle are now the key tests of whether the pipeline converts into a durably growing top line. Until it does, the miss and the repeated slippage in the profitability target will weigh more heavily than the 90% gross margin.